gamma-aminobutyric acid has been researched along with Neoplasms in 76 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 9.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 9.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Although gabapentin might be regarded as a promising new adjuvant analgesic for neuropathic cancer pain, our results indicated that the decrease in pain score was of minimal clinical benefit." | 9.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 9.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 9.11 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 9.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 9.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 8.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 8.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Management of patients with cancer suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge." | 6.84 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Gabapentin/placebo was started the day of chemotherapy and continued through day 5 for the first chemotherapy cycle, whereas dex was titrated down on days 2-4." | 6.79 | Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). ( Barton, DL; Blair, SC; Diekmann, B; Fuloria, J; Jaslowski, AJ; Kottschade, LA; Loprinzi, CL; Lyss, AP; Mazurczak, MA; Sloan, JA; Terstriep, S; Thanarajasingam, G, 2014) |
| "Gabapentin was initiated in addition to the drugs currently being administered." | 6.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Neuropathic pain is regarded as one of the main causes of cancer pain refractory to standard opioid therapy in palliative care." | 6.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| " The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 6.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Seizures were controlled in 49% of 59 children in whom gabapentin was added to other antiepilepsy drugs: 43% of the leukemia group, 53% of the brain tumor group, and 50% of the other tumor group." | 6.71 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 6.71 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "Gabapentin was dose-escalated from 300 mg/d to 1." | 6.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 6.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Somnolence, mental clouding, and headache were the most frequently reported adverse events." | 6.70 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 6.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "All were already treated for their pain syndrome." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "We prospectively followed 20 cancer patients with advanced disease suffering from neuropathic pain." | 5.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| " The inclusion criteria are adult patients with cancer suffering from neuropathic cancer pain refractory to opioids and gabapentinoids, patients with a Numerical Rating Scale (NRS) pain score of 4 or higher and patients with a total Hospital Anxiety and Depression Scale score of less than 20." | 5.24 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN)." | 5.22 | Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. ( Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G, 2016) |
| "The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only." | 5.17 | The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients. ( Aielli, F; Casuccio, A; Codipietro, L; Ferrera, P; Lo Presti, C; Mercadante, S; Porzio, G, 2013) |
| "The clinical usefulness of gabapentin in combination with opioids for Japanese patients with neuropathic cancer pain was assessed in an open-label, single-center, prospective study." | 5.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Although gabapentin might be regarded as a promising new adjuvant analgesic for neuropathic cancer pain, our results indicated that the decrease in pain score was of minimal clinical benefit." | 5.14 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-imipramine significantly decreased the total pain score and daily paroxysmal pain episodes." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 5.14 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| " At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 5.11 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "This study evaluated the effectiveness of gabapentin to treat cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "We conclude that gabapentin is an effective treatment for cancer-related neuropathic pain." | 5.11 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "The aim of our study was to explore a potential analgesic effect of gabapentin in patients with neuropathic pain caused by anticancer treatment." | 5.10 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| " Overall, there was a low quality of evidence that gabapentin, pregabalin, amitriptyline, and venlafaxine were effective in reducing pain intensity in patients with cancer pain." | 4.95 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "Gabapentin (GBP), originally an antiepileptic drug, is more commonly used in the treatment of neuropathic pain." | 4.90 | Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain. ( Butler, PM; Kurowski, D; Perloff, MD; Yan, PZ, 2014) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Recent studies showed effectiveness of gabapentin in improving the pain control in patients with neuropathic cancer pain, already treated with opiates." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Given the significant benefits of gabapentin and the combination of gabapentin with opioids for the treatment of neuropathic pain, randomized clinical trials are needed to establish the role of these analgesic regimens for the treatment of neuropathic cancer pain." | 4.86 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| " Data pertaining to demographics, diagnosis, oral morphine dose equivalent of the opioid at the time of discharge, adjuvant analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), and pain scores as reported by nurses and physicians were collected." | 3.81 | Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015) |
| "Little is known about current practice in using the anticonvulsant gabapentin in the management of cancer-related neuropathic pain." | 3.72 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "The main objective of this study was to describe the pattern of gabapentin use as an adjuvant analgesic for cancer-related neuropathic pain in patients admitted to a tertiary palliative care unit." | 3.72 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "In the development of cancer cells, it plays oncogenesis- related roles." | 3.01 | Various Effects of the GABAergic System on Cancer: The Conditions and Specificities of its use in the Treatment of Some Cancers. ( Dehkordi, HT; Eliyasi Dashtaki, M; Ghasemi, S, 2023) |
| "Management of patients with cancer suffering from neuropathic pain refractory to opioids and gabapentinoids remains an important challenge." | 2.84 | Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. ( Ariyoshi, K; Ishiki, H; Iwase, S; Kawaguchi, T; Kizawa, Y; Koyama, A; Matsuda, Y; Matsuoka, H; Miyaji, T; Morita, T; Yamaguchi, T, 2017) |
| "Paclitaxel can cause an acute pain syndrome (P-APS), considered to be an acute form of neuropathy and chronic chemotherapy-induced peripheral neuropathy (CIPN)." | 2.82 | Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial. ( Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G, 2016) |
| "Neuropathic cancer pain (NCP) is a common manifestation of cancer and/or its treatment." | 2.79 | Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. ( Argyra, E; Melemeni, A; Raptis, E; Siafaka, I; Stavropoulou, E; Vadalouca, A, 2014) |
| "Prompt use of a neuropathic pain-specific adjuvant, such as pregabalin, in NCP may lead to better control of the neuropathic component, with opioid-sparing effects." | 2.79 | Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. ( Argyra, E; Melemeni, A; Raptis, E; Siafaka, I; Stavropoulou, E; Vadalouca, A, 2014) |
| "Gabapentin/placebo was started the day of chemotherapy and continued through day 5 for the first chemotherapy cycle, whereas dex was titrated down on days 2-4." | 2.79 | Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance). ( Barton, DL; Blair, SC; Diekmann, B; Fuloria, J; Jaslowski, AJ; Kottschade, LA; Loprinzi, CL; Lyss, AP; Mazurczak, MA; Sloan, JA; Terstriep, S; Thanarajasingam, G, 2014) |
| " The primary endpoint was a ≥1/3 reduction in pain (NRS); secondary endpoints included the time to analgesia and adverse effects." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Patients (N = 75) with oncological neuropathic pain, previously untreated with pregabalin, were recruited in 5 Italian institutions between 2007 and 2010." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Both strategies effectively controlled neuropathic pain, but according to the adopted selection design arm A is preferable to arm B for pain control." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Neuropathic pain is commonly associated with cancer." | 2.78 | Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. ( Bianchi, A; Bramati, A; Carbone, C; Farina, G; Febbraro, A; Ganzinelli, M; Garassino, MC; Gentili, M; Iorno, V; La Verde, N; Marabese, M; Moretti, A; Piva, S; Spagnoletti, I; Torri, V, 2013) |
| "Oral morphine was used for rescue analgesic for continued pain." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "A total of 120 patients with cancer having severe neuropathic cancer pain were enrolled in the study after taking approval from Institutional Ethics Committee and divided in to 4 groups: group AT-amitriptyline, group GB-gabapentin, group PG-pregabalin, and group PL-placebo." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Neuropathic pain is difficult to diagnose and difficult to treat with certainty." | 2.77 | A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. ( Bhatnagar, S; Goyal, GN; Mishra, S; Rana, SP; Upadhya, SP, 2012) |
| "Neuropathic pain frequently occurs in cancer patients, but no drug therapy has been established for this type of disorder." | 2.77 | Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. ( Fujisaka, Y; Kaneda, H; Koyama, A; Makimura, C; Matsuoka, H; Nakagawa, K; Okamoto, W; Otsuka, M; Tsurutani, J, 2012) |
| "The subjects of the study were 15 cancer patients with neuropathic pain who visited the Kinki University Faculty of Medicine Hospital and met the International Association for the Study of Pain diagnostic criteria for neuropathic pain." | 2.77 | Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. ( Fujisaka, Y; Kaneda, H; Koyama, A; Makimura, C; Matsuoka, H; Nakagawa, K; Okamoto, W; Otsuka, M; Tsurutani, J, 2012) |
| "Gabapentin was initiated in addition to the drugs currently being administered." | 2.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| "Neuropathic pain is regarded as one of the main causes of cancer pain refractory to standard opioid therapy in palliative care." | 2.75 | A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain. ( Shimoyama, N; Takahashi, H, 2010) |
| " The aim of this study was to see whether low-dose gabapentin is effective in treating cancer-related neuropathic pain when combined with low-dose imipramine." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Low-dose gabapentin-antidepressant combination with opioids was effective in managing neuropathic cancer pain without severe adverse effects." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Painful neuropathic conditions of cancer pain often show little response to nonopioid and opioid analgesics but may be eased by antidepressants and anticonvulsants." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Fifty-two cancer patients diagnosed as having neuropathic pain were allocated into four groups: G400-I group took gabapentin 200 mg and imipramine 10 mg every 12 h orally; G400 group took gabapentin 200 mg every 12 h orally; G800 group took gabapentin 400 mg every 12 h orally; I group took imipramine 10 mg every 12 h orally." | 2.75 | Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine. ( Arai, YC; Arakawa, M; Hayashi, R; Kinoshita, A; Kobayashi, K; Kondo, M; Matsubara, S; Matsubara, T; Nishida, K; Nishihara, M; Shimo, K; Suetomi, K; Suzuki, C; Tohyama, Y; Ushida, T, 2010) |
| "Neuropathic cancer pain represents a major challenge." | 2.73 | Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial. ( Aydinli, I; Keskinbora, K; Pekel, AF, 2007) |
| "If, however, those cancers have functional GABA receptors that participate in GABAergic signaling, it raises an important question whether these signaling pathways might be targetable for therapeutic benefit." | 2.72 | Therapeutically leveraging GABA ( Bhattacharya, D; Gawali, VS; Kallay, L; Koehler, A; Krummel, DP; Sengupta, S; Stambrook, P; Toukam, DK, 2021) |
| "Cancer is one of the leading causes of death in both developed and developing countries." | 2.72 | The Emerging Roles of π Subunit-Containing GABA ( Has, ATC; Hassan, Z; Juvale, IIA, 2021) |
| "Seizures were controlled in 49% of 59 children in whom gabapentin was added to other antiepilepsy drugs: 43% of the leukemia group, 53% of the brain tumor group, and 50% of the other tumor group." | 2.71 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "At our institution, new-onset seizures in children on chemotherapy are treated with gabapentin, a nonhepatic enzyme inducer." | 2.71 | Gabapentin to control seizures in children undergoing cancer treatment. ( Hunt, DL; Khan, RB; Thompson, SJ, 2004) |
| "Gabapentin was dose-escalated from 300 mg/d to 1." | 2.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Gabapentin has been evaluated in the treatment of nonmalignant neuropathic pain, however, there is little direct evidence evaluating its efficacy in cancer-related neuropathic pain." | 2.71 | Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. ( A'hern, R; Broadley, K; Goller, K; Hardy, J; Riley, J; Ross, JR; Williams, J, 2005) |
| "Somnolence, mental clouding, and headache were the most frequently reported adverse events." | 2.70 | Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. ( Bosnjak, S; Jelic, S; Luki, V; Susnjar, S, 2002) |
| "Gabapentin was administered as an "add on" therapy to 22 patients with neuropathic cancer pain only partially responsive to opioid therapy." | 2.69 | Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. ( Caraceni, A; De Conno, F; Martini, C; Zecca, E, 1999) |
| "To update our guidelines for the treatment of pain in patients with cancer, we performed a systematic review on the use of adjuvant analgesics in pain in cancer." | 2.55 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "In patients with cancer, pain is one of the most feared and burdensome symptoms." | 2.55 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "The treatment of pain associated with cancer should be tailored to the patient's personal preferences." | 2.55 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "Multiple causes of neuropathic pain have been described and its incidence is likely to increase owing to the ageing global population, increased incidence of diabetes mellitus and improved survival from cancer after chemotherapy." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibres (Aβ, Aδ and C fibres) and central neurons, and affects 7-10% of the general population." | 2.55 | Neuropathic pain. ( Attal, N; Baron, R; Bennett, DL; Bouhassira, D; Colloca, L; Dickenson, AH; Dworkin, RH; Eccleston, C; Finnerup, NB; Freeman, R; Kalso, E; Ludman, T; Raja, SN; Truini, A; Yarnitsky, D, 2017) |
| "Opioid-induced hyperalgesia has recently been described as representing a challenge for physicians in the clinical setting." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Whereas most pain due to cancer can be relieved with relatively simple methods using oral analgesics, as suggested by WHO guidelines, some patients may have difficult pain situations that require more complex approaches." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Neuropathic pain is usually considered an "hard pain" both for the intrinsic difficulties in a correct diagnosis, and for the modest efficacy of the most part of conventional treatments." | 2.47 | [Neuropathic pain in oncology. Novel evidence for clinical practice]. ( Carloni, F; Castellani, C; Drudi, F; Possenti, C; Santelmo, C; Tassinari, D, 2011) |
| "Gabapentin was initially developed as an antiepileptic drug but was later discovered to be an effective treatment of neuropathic pain." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Gabapentin has been successfully used for the treatment of multiple neuropathic pain syndromes such as diabetic neuropathy and postherpetic neuralgia." | 2.46 | Gabapentin for the treatment of cancer-related pain syndromes. ( Bar Ad, V, 2010) |
| "Many cancers have an unusual dependence on glutamine." | 1.72 | Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. ( Alexander, PB; Li, QJ; Liang, Y; Mudgal, P; Pan, C; Qin, D; Tan, L; Thompson, JW; Wan, Y; Wang, XF; Wang, Y; Wu, H; Yin, T; Yuan, L, 2022) |
| "The striking metabolic overlap between cancer and neurological diseases sheds light on novel therapeutic strategies for cancer treatment." | 1.62 | Bridging the Metabolic Parallels Between Neurological Diseases and Cancer. ( Gu, Y; Guo, S; Le, A; Qu, J, 2021) |
| "Cancer pain is complex, and despite the introduction of the WHO cancer pain ladder, few studies have looked at the prevalence of adjuvant medication use in an inpatient palliative medicine unit." | 1.42 | Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements? ( Davis, MP; Gordon, P; Gross, J; Sharma, P; Shinde, S, 2015) |
| " In 28-37% of patients, pregabalin was associated with adverse events, with drowsiness and dizziness being frequently observed." | 1.39 | [Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy]. ( Itabashi, T; Kashiwaba, M; Kudo, K; Nihei, S; Sato, J; Takahashi, K, 2013) |
| "These cancers were not statistically significantly associated with gabapentin in the GPRD case-control studies (2-year lag)." | 1.38 | Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. ( Boudiaf, N; Friedman, GD; Habel, LA; Irizarry, MC; Logie, J; Udaltsova, N; Webb, DJ, 2012) |
| "Bioenergetic profiling of tumors is a new challenge of cancer research and medicine as therapies are currently being developed." | 1.38 | Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes. ( Allen, G; Bellance, N; Nagrath, D; Pabst, L; Rossignol, R, 2012) |
| "Three patients with cancer experienced severe side-effects after starting anti-neuropathic pain therapy." | 1.37 | [Pitfalls in the treatment of neuropathic pain in patients with cancer]. ( Engels, Y; Hekster, YA; Schalkwijk, A; Verhagen, CA; Vissers, KC, 2011) |
| "A previous study of cancer-related neuropathic pain (NP) found that a 10-fold increase in pregabalin (PGB) use increased patients' satisfaction with treatment." | 1.37 | Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health. ( Ciria, JP; Fernández, MC; Gonzálvez, ML; López-Gómez, V; Mańas, A; Masramon, X; Morillo, V; Pérez, M, 2011) |
| "4%) with gabapentin at a dosage of 900 mg/d and in 9 patients (20." | 1.36 | Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience. ( Aielli, F; Aloisi, P; Ficorella, C; Galletti, B; Porzio, G; Verna, L, 2010) |
| "Gabapentin seems to be a safe and effective treatment for idiopathic sweating in advanced cancer patients." | 1.33 | Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. ( Aielli, F; Aloisi, P; Cannita, K; Ficorella, C; Marchetti, P; Porto, C; Porzio, G; Ricevuto, E; Verna, L, 2006) |
| "Nine patients with advanced cancer suffering from idiopathic severe sweating were treated with gabapentin (600-1,800 mg/day)." | 1.33 | Gabapentin in the treatment of severe sweating experienced by advanced cancer patients. ( Aielli, F; Aloisi, P; Cannita, K; Ficorella, C; Marchetti, P; Porto, C; Porzio, G; Ricevuto, E; Verna, L, 2006) |
| "Four were cancer patients and one suffered from neuropathic pain in the neck (C3)." | 1.33 | Experience with gabapentin for neuropathic pain in adolescents: report of five cases. ( Butkovic, D; Mihovilovic-Novak, B; Toljan, S, 2006) |
| "Gabapentin was the most widely used AED (92% of all AED patients); amitriptyline was the most widely used TCA (79% of all TCA patients)." | 1.33 | Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain. ( Berger, A; Dukes, E; Mercadante, S; Oster, G, 2006) |
| "Gabapentin was discontinued in 10 patients (46%)." | 1.32 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "Of the 147 patients with a cancer diagnosis, 45 (31%) had neuropathic pain." | 1.32 | The pattern of gabapentin use in a tertiary palliative care unit. ( al-Shahri, MZ; Oneschuk, D, 2003) |
| "Gabapentin (GBP) is a new antiepileptic agent with an original spectrum of activity." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "All were already treated for their pain syndrome." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| "We prospectively followed 20 cancer patients with advanced disease suffering from neuropathic pain." | 1.32 | [Gabapentin (Neurontin) and cancer pain: a pilot study]. ( Body, JJ; Lossignol, DA; Plehiers, B, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.95) | 18.7374 |
| 1990's | 2 (2.63) | 18.2507 |
| 2000's | 24 (31.58) | 29.6817 |
| 2010's | 35 (46.05) | 24.3611 |
| 2020's | 12 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Bhattacharya, D | 1 |
| Gawali, VS | 1 |
| Kallay, L | 1 |
| Toukam, DK | 1 |
| Koehler, A | 1 |
| Stambrook, P | 1 |
| Krummel, DP | 1 |
| Sengupta, S | 1 |
| Zhang, B | 1 |
| Vogelzang, A | 1 |
| Miyajima, M | 1 |
| Sugiura, Y | 1 |
| Wu, Y | 1 |
| Chamoto, K | 1 |
| Nakano, R | 1 |
| Hatae, R | 1 |
| Menzies, RJ | 1 |
| Sonomura, K | 1 |
| Hojo, N | 1 |
| Ogawa, T | 1 |
| Kobayashi, W | 1 |
| Tsutsui, Y | 1 |
| Yamamoto, S | 1 |
| Maruya, M | 1 |
| Narushima, S | 1 |
| Suzuki, K | 1 |
| Sugiya, H | 1 |
| Murakami, K | 1 |
| Hashimoto, M | 1 |
| Ueno, H | 1 |
| Kobayashi, T | 1 |
| Ito, K | 1 |
| Hirano, T | 1 |
| Shiroguchi, K | 1 |
| Matsuda, F | 1 |
| Suematsu, M | 1 |
| Honjo, T | 1 |
| Fagarasan, S | 1 |
| Juvale, IIA | 1 |
| Hassan, Z | 1 |
| Has, ATC | 1 |
| Gilardi, M | 1 |
| Ramos, M | 1 |
| Hollern, D | 1 |
| Wang, Y | 1 |
| Thompson, JW | 1 |
| Yin, T | 1 |
| Alexander, PB | 2 |
| Qin, D | 1 |
| Mudgal, P | 1 |
| Wu, H | 1 |
| Liang, Y | 1 |
| Tan, L | 1 |
| Pan, C | 1 |
| Yuan, L | 1 |
| Wan, Y | 1 |
| Li, QJ | 2 |
| Wang, XF | 2 |
| Huang, W | 1 |
| Cao, L | 1 |
| Sahafi-Pour, SA | 1 |
| Shirmardi, SP | 2 |
| Saeedzadeh, E | 1 |
| Baradaran, S | 1 |
| Sadeghi, M | 1 |
| Rue, MCP | 1 |
| Baas-Thomas, N | 1 |
| Iyengar, PS | 1 |
| Scaria, LK | 1 |
| Marder, E | 1 |
| Lim, JS | 1 |
| Kim, CR | 1 |
| Shin, KS | 1 |
| Park, HJ | 1 |
| Yoon, TJ | 1 |
| Dehkordi, HT | 1 |
| Ghasemi, S | 1 |
| Eliyasi Dashtaki, M | 1 |
| Guo, S | 1 |
| Gu, Y | 1 |
| Qu, J | 1 |
| Le, A | 1 |
| Matsuoka, H | 2 |
| Ishiki, H | 1 |
| Iwase, S | 1 |
| Koyama, A | 2 |
| Kawaguchi, T | 1 |
| Kizawa, Y | 1 |
| Morita, T | 1 |
| Matsuda, Y | 1 |
| Miyaji, T | 1 |
| Ariyoshi, K | 1 |
| Yamaguchi, T | 1 |
| Raptis, E | 1 |
| Vadalouca, A | 1 |
| Stavropoulou, E | 1 |
| Argyra, E | 1 |
| Melemeni, A | 1 |
| Siafaka, I | 1 |
| Garassino, MC | 1 |
| Piva, S | 1 |
| La Verde, N | 1 |
| Spagnoletti, I | 1 |
| Iorno, V | 1 |
| Carbone, C | 1 |
| Febbraro, A | 1 |
| Bianchi, A | 1 |
| Bramati, A | 1 |
| Moretti, A | 1 |
| Ganzinelli, M | 1 |
| Marabese, M | 1 |
| Gentili, M | 1 |
| Torri, V | 1 |
| Farina, G | 1 |
| Pfisterer, M | 1 |
| Wang, H | 1 |
| Gomez, DR | 1 |
| Liao, Z | 1 |
| Bennett, MI | 1 |
| Laird, B | 1 |
| van Litsenburg, C | 1 |
| Nimour, M | 1 |
| Nihei, S | 1 |
| Sato, J | 1 |
| Kashiwaba, M | 1 |
| Itabashi, T | 1 |
| Kudo, K | 1 |
| Takahashi, K | 1 |
| Yan, PZ | 1 |
| Butler, PM | 1 |
| Kurowski, D | 1 |
| Perloff, MD | 1 |
| Mercadante, S | 4 |
| Hershman, DL | 1 |
| Lacchetti, C | 1 |
| Dworkin, RH | 2 |
| Lavoie Smith, EM | 1 |
| Bleeker, J | 1 |
| Cavaletti, G | 1 |
| Chauhan, C | 1 |
| Gavin, P | 1 |
| Lavino, A | 1 |
| Lustberg, MB | 1 |
| Paice, J | 1 |
| Schneider, B | 1 |
| Smith, ML | 1 |
| Smith, T | 1 |
| Terstriep, S | 2 |
| Wagner-Johnston, N | 1 |
| Bak, K | 1 |
| Loprinzi, CL | 3 |
| Nanga, RP | 1 |
| DeBrosse, C | 1 |
| Singh, A | 1 |
| D'Aquilla, K | 1 |
| Hariharan, H | 1 |
| Reddy, R | 1 |
| Barton, DL | 1 |
| Thanarajasingam, G | 1 |
| Sloan, JA | 1 |
| Diekmann, B | 1 |
| Fuloria, J | 1 |
| Kottschade, LA | 1 |
| Lyss, AP | 1 |
| Jaslowski, AJ | 1 |
| Mazurczak, MA | 1 |
| Blair, SC | 1 |
| Shinde, S | 1 |
| Gordon, P | 1 |
| Sharma, P | 1 |
| Gross, J | 1 |
| Davis, MP | 1 |
| Shinde, SS | 1 |
| Seisler, D | 1 |
| Soori, G | 1 |
| Atherton, PJ | 1 |
| Pachman, DR | 1 |
| Lafky, J | 1 |
| Ruddy, KJ | 1 |
| Kottschade, L | 1 |
| Novotny, P | 1 |
| Lyss, A | 1 |
| Mazurczak, M | 1 |
| Loprinzi, C | 1 |
| Barton, D | 1 |
| van den Beuken-van Everdingen, MH | 1 |
| de Graeff, A | 1 |
| Jongen, JL | 1 |
| Dijkstra, D | 1 |
| Mostovaya, I | 1 |
| Vissers, KC | 2 |
| Colloca, L | 1 |
| Ludman, T | 1 |
| Bouhassira, D | 1 |
| Baron, R | 1 |
| Dickenson, AH | 1 |
| Yarnitsky, D | 1 |
| Freeman, R | 1 |
| Truini, A | 1 |
| Attal, N | 1 |
| Finnerup, NB | 1 |
| Eccleston, C | 1 |
| Kalso, E | 1 |
| Bennett, DL | 1 |
| Raja, SN | 1 |
| Taira, T | 1 |
| Vondracek, P | 1 |
| Oslejskova, H | 1 |
| Kepak, T | 1 |
| Mazanek, P | 1 |
| Sterba, J | 1 |
| Rysava, M | 1 |
| Gal, P | 1 |
| Weis, SM | 1 |
| Stupack, DG | 1 |
| Cheresh, DA | 1 |
| Young, SZ | 1 |
| Bordey, A | 1 |
| Doi, Y | 1 |
| Furukawa, F | 1 |
| Suguro, M | 1 |
| Ito, H | 1 |
| Imai, N | 1 |
| Nabae, K | 1 |
| Toda, Y | 1 |
| Inatomi, S | 1 |
| Kinugasa, S | 1 |
| Kobayashi, H | 1 |
| Takahashi, H | 1 |
| Shimoyama, N | 1 |
| Arai, YC | 1 |
| Matsubara, T | 1 |
| Shimo, K | 1 |
| Suetomi, K | 1 |
| Nishihara, M | 1 |
| Ushida, T | 1 |
| Kobayashi, K | 1 |
| Suzuki, C | 1 |
| Kinoshita, A | 1 |
| Kondo, M | 1 |
| Matsubara, S | 1 |
| Hayashi, R | 1 |
| Tohyama, Y | 1 |
| Nishida, K | 1 |
| Arakawa, M | 1 |
| Porzio, G | 3 |
| Aielli, F | 3 |
| Verna, L | 2 |
| Aloisi, P | 2 |
| Galletti, B | 1 |
| Ficorella, C | 2 |
| Bar Ad, V | 1 |
| Sirven, JI | 1 |
| Schalkwijk, A | 1 |
| Verhagen, CA | 1 |
| Engels, Y | 1 |
| Hekster, YA | 1 |
| Tassinari, D | 1 |
| Drudi, F | 1 |
| Carloni, F | 1 |
| Possenti, C | 1 |
| Santelmo, C | 1 |
| Castellani, C | 1 |
| Gandomkar, M | 1 |
| Maragheh, MG | 1 |
| Shamsaei, M | 1 |
| Mishra, S | 1 |
| Bhatnagar, S | 1 |
| Goyal, GN | 1 |
| Rana, SP | 1 |
| Upadhya, SP | 1 |
| Mańas, A | 1 |
| Ciria, JP | 1 |
| Fernández, MC | 1 |
| Gonzálvez, ML | 1 |
| Morillo, V | 1 |
| Pérez, M | 1 |
| Masramon, X | 1 |
| López-Gómez, V | 1 |
| Irizarry, MC | 1 |
| Webb, DJ | 1 |
| Boudiaf, N | 1 |
| Logie, J | 1 |
| Habel, LA | 1 |
| Udaltsova, N | 1 |
| Friedman, GD | 1 |
| Baba, M | 1 |
| Gomyo, I | 1 |
| Ferrera, P | 1 |
| Codipietro, L | 1 |
| Lo Presti, C | 1 |
| Casuccio, A | 1 |
| Anand, S | 1 |
| Makimura, C | 1 |
| Otsuka, M | 1 |
| Okamoto, W | 1 |
| Fujisaka, Y | 1 |
| Kaneda, H | 1 |
| Tsurutani, J | 1 |
| Nakagawa, K | 1 |
| Bellance, N | 1 |
| Pabst, L | 1 |
| Allen, G | 1 |
| Rossignol, R | 1 |
| Nagrath, D | 1 |
| Ortega, A | 1 |
| ORITA, K | 1 |
| MIYAKE, I | 1 |
| Oneschuk, D | 1 |
| al-Shahri, MZ | 1 |
| Szczaurska, K | 1 |
| Mazurkiewicz, M | 1 |
| Opolski, A | 1 |
| Khan, RB | 1 |
| Hunt, DL | 1 |
| Thompson, SJ | 1 |
| Oh, CH | 1 |
| Oh, SH | 1 |
| Lossignol, DA | 1 |
| Plehiers, B | 1 |
| Body, JJ | 1 |
| Prommer, E | 1 |
| Ross, JR | 1 |
| Goller, K | 1 |
| Hardy, J | 1 |
| Riley, J | 1 |
| Broadley, K | 1 |
| A'hern, R | 1 |
| Williams, J | 1 |
| Porto, C | 1 |
| Cannita, K | 1 |
| Ricevuto, E | 1 |
| Marchetti, P | 1 |
| Butkovic, D | 1 |
| Toljan, S | 1 |
| Mihovilovic-Novak, B | 1 |
| Berger, A | 1 |
| Dukes, E | 1 |
| Oster, G | 1 |
| Choudhuri, I | 1 |
| Sarvananthan, N | 1 |
| Gottlob, I | 1 |
| Maubant, S | 1 |
| Saint-Dizier, D | 1 |
| Boutillon, M | 1 |
| Perron-Sierra, F | 1 |
| Casara, PJ | 1 |
| Hickman, JA | 1 |
| Tucker, GC | 1 |
| Van Obberghen-Schilling, E | 1 |
| Watanabe, M | 1 |
| Maemura, K | 1 |
| Oki, K | 1 |
| Shiraishi, N | 1 |
| Shibayama, Y | 1 |
| Katsu, K | 1 |
| Keskinbora, K | 1 |
| Pekel, AF | 1 |
| Aydinli, I | 1 |
| Prasad, GC | 1 |
| Chaurasiya, J | 1 |
| Mohanty, S | 1 |
| McCaffery, M | 1 |
| Caraceni, A | 2 |
| Zecca, E | 2 |
| Martini, C | 2 |
| De Conno, F | 2 |
| Chandler, A | 1 |
| Williams, JE | 1 |
| Villari, P | 1 |
| Fulfaro, F | 1 |
| Bosnjak, S | 1 |
| Jelic, S | 1 |
| Susnjar, S | 1 |
| Luki, V | 1 |
| Garrido, JC | 1 |
| Lagos, RE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients[NCT04855578] | 160 participants (Actual) | Interventional | 2021-05-28 | Completed | |||
| Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial[NCT03080493] | Phase 4 | 121 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| Intravenous Lidocaine Infusion Versus Oral Duloxetine For The Prevention And Treatment Of Chemotherapy Induced Peripheral Neuropathy Among Breast Cancer Patients[NCT04732455] | 60 participants (Actual) | Interventional | 2021-01-15 | Completed | |||
| The Use of Cryotherapy to Prevent Paclitaxel-induced Peripheral Neuropathy and Nail Changes in Women With Breast Cancer[NCT04558034] | 14 participants (Actual) | Interventional | 2020-08-04 | Terminated (stopped due to Principal Investigator retired before study completed.) | |||
| Effect of Cryotherapy in Controlling Peripheral Neuropathy in Cancer Children[NCT04536207] | 60 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | |||
| Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534] | 29 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| Drug Repurposing for the Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)[NCT04780854] | Phase 2 | 68 participants (Anticipated) | Interventional | 2020-11-03 | Recruiting | ||
| Effectiveness and Cost-effectiveness of Ozone Therapy in Patients With Pain Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (O3NPIQ)[NCT04299893] | Phase 2/Phase 3 | 42 participants (Anticipated) | Interventional | 2020-11-30 | Recruiting | ||
| Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884] | 150 participants (Anticipated) | Interventional | 2023-05-31 | Not yet recruiting | |||
| PUCE Study: Prevention of Unmitigated Chemotherapy-induced Emesis[NCT03996863] | 0 participants (Actual) | Interventional | 2019-08-01 | Withdrawn (stopped due to Drexel Oncology was shut down a few days before first patient in.) | |||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome: a Multicenter, Randomized, Doubleblind, Placebo-controlled Study[NCT05411900] | Phase 2 | 164 participants (Anticipated) | Interventional | 2022-05-25 | Recruiting | ||
| Neuropathic Foot and Ankle in Rheumatoid Arthritis : Ultrasound and Nerve Conduction Study[NCT04550884] | 80 participants (Anticipated) | Observational | 2020-10-31 | Not yet recruiting | |||
| NanaBis™ an Oro-buccal Administered Equimolar d9-THC & CBD Formulation as Monotherapy for Management of Opioid Requiring Bone Pain Due to Metastatic Cancer: Phase 3 Multi Centre Blinded Randomized Withdrawal Active & Placebo Controlled Trial[NCT04808531] | Phase 3 | 360 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117] | Early Phase 1 | 48 participants (Anticipated) | Interventional | 2022-10-11 | Enrolling by invitation | ||
| Double Blind Trial Investigating the Role of Sulfasalazine in Decreasing Opioids Requirements in Breast Cancer Patients[NCT03847311] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-05-03 | Recruiting | ||
| Comparison of Oral Gabapentin and Pregabalin in Postoperative Pain Control After Photorefractive Keratectomy: a Prospective, Randomized Study.[NCT00954187] | 8 participants (Actual) | Interventional | 2009-11-30 | Terminated (stopped due to PI left institution) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 2 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 3.5 |
| Placebo Oral Capsule | 4 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 4 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Mean) |
|---|---|
| Gabapentin | 3 |
| Placebo Oral Capsule | 3.5 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person before subject leaves clinic appointment. (NCT03080493)
Timeframe: 5 minutes after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 1 |
| Placebo Oral Capsule | 2 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained via text message. (NCT03080493)
Timeframe: 8 hours after insertion of last osmotic dilator
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 2 |
| Placebo Oral Capsule | 2.5 |
Pain score based on numeric rating scale (NRS [0 lowest value to 10 highest value, in which 0 is the lowest amount of pain and 10 is the highest amount of pain]); Baseline obtained prior to study drug ingestion/dilator insertion. NRS pain score obtained in person upon presentation for D&E procedure. (NCT03080493)
Timeframe: Time of presentation for D&E (day after dilator insertion)
| Intervention | Numeric rating scale pain score change (Median) |
|---|---|
| Gabapentin | 0.5 |
| Placebo Oral Capsule | 1 |
Subject account of how many used acetaminophen/codeine (standard medications given for supplement NSAID as needed after dilator insertion) (NCT03080493)
Timeframe: Collected between each subject contact (2 hours, 4 hours, 8 hours after dilator insertion and at time of presentation for D&E procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Gabapentin | 35 |
| Placebo Oral Capsule | 40 |
19 reviews available for gamma-aminobutyric acid and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Therapeutically leveraging GABA
Topics: Animals; gamma-Aminobutyric Acid; Humans; Neoplasms; Receptors, GABA-A; Signal Transduction | 2021 |
The Emerging Roles of π Subunit-Containing GABA
Topics: Animals; Female; gamma-Aminobutyric Acid; Humans; Neoplasms; Receptors, GABA-A | 2021 |
GABAergic signaling beyond synapses: an emerging target for cancer therapy.
Topics: Animals; gamma-Aminobutyric Acid; Humans; Mammals; Neoplasms; Neurons; Neurotransmitter Agents; Sign | 2023 |
Various Effects of the GABAergic System on Cancer: The Conditions and Specificities of its use in the Treatment of Some Cancers.
Topics: Animals; Brain; gamma-Aminobutyric Acid; Humans; Neoplasms | 2023 |
Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature.
Topics: Analgesics; gamma-Aminobutyric Acid; Humans; Neoplasms; Neuralgia; Pregabalin | 2013 |
Beyond neuropathic pain: gabapentin use in cancer pain and perioperative pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Neopla | 2014 |
Managing difficult pain conditions in the cancer patient.
Topics: Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Cyclohexanec | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.
Topics: Adult; Amines; Amitriptyline; Analgesics; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineo | 2014 |
Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.
Topics: Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy, Adjuvant; Cyclohexanecarbo | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
Neuropathic pain.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Gabapentin; gamma-Aminob | 2017 |
[Chronic intrathecal drug administration for the control of intractable pain].
Topics: Amines; Analgesics, Opioid; Anesthetics, Local; Baclofen; Calcium Channel Blockers; Clonidine; Cyclo | 2008 |
GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches.
Topics: Adult Stem Cells; Animals; Cell Division; Embryonic Stem Cells; gamma-Aminobutyric Acid; Humans; Neo | 2009 |
Gabapentin for the treatment of cancer-related pain syndromes.
Topics: Amines; Analgesics; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2010 |
[Neuropathic pain in oncology. Novel evidence for clinical practice].
Topics: Amines; Amitriptyline; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2011 |
Gabapentin for pruritus in palliative care.
Topics: Amines; Analgesics, Opioid; Burns; Cholestasis; Cyclohexanecarboxylic Acids; Dermatologic Agents; Ga | 2013 |
A new role for GABA: inhibition of tumor cell migration.
Topics: Animals; Baclofen; Cell Movement; GABA Agonists; gamma-Aminobutyric Acid; Humans; Neoplasm Invasiven | 2003 |
[The role of GABA-ergic system in carcinogenesis].
Topics: Breast Neoplasms; Central Nervous System; Colonic Neoplasms; Digestive System Neoplasms; Female; gam | 2003 |
Gamma-aminobutyric acid (GABA) and cell proliferation: focus on cancer cells.
Topics: Animals; Cell Differentiation; Cell Movement; Cell Proliferation; gamma-Aminobutyric Acid; Humans; M | 2006 |
17 trials available for gamma-aminobutyric acid and Neoplasms
| Article | Year |
|---|---|
Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cancer Pain; Cyclohexanecarboxylic Acids; Doubl | 2017 |
Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study.
Topics: Aged; Analgesics, Opioid; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neoplasms; Neu | 2014 |
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 2013 |
Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance).
Topics: Adult; Aged; Amines; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Double-Blind Method; Drug A | 2014 |
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Topics: Acute Pain; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Topics: Adult; Aged; Amines; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclohexanecarboxylic Acids; Dru | 2016 |
Efficacy of pregabalin in neuropathic pain in paediatric oncological patients.
Topics: Adolescent; Analgesics; Antineoplastic Agents; Child; Female; Follow-Up Studies; gamma-Aminobutyric | 2009 |
A prospective open-label trial of gabapentin as an adjuvant analgesic with opioids for Japanese patients with neuropathic cancer pain.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Female; Gabapentin | 2010 |
Low-dose gabapentin as useful adjuvant to opioids for neuropathic cancer pain when combined with low-dose imipramine.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study.
Topics: Adult; Amines; Amitriptyline; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Double- | 2012 |
The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients.
Topics: Analgesics; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; | 2013 |
Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.
Topics: Adult; Aged; Analgesics; Antidepressive Agents; Duloxetine Hydrochloride; Female; gamma-Aminobutyric | 2012 |
Gabapentin to control seizures in children undergoing cancer treatment.
Topics: Acetates; Amines; Anticonvulsants; Antineoplastic Agents; Brain; Child; Cyclohexanecarboxylic Acids; | 2004 |
Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study.
Topics: Aged; Amines; Analgesics; Analysis of Variance; Cyclohexanecarboxylic Acids; Dose-Response Relations | 2005 |
Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial.
Topics: Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Comb | 2007 |
Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Cyclohexane | 1999 |
Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study.
Topics: Acetates; Adolescent; Amines; Analgesics; Antineoplastic Agents; Cyclohexanecarboxylic Acids; Female | 2002 |
40 other studies available for gamma-aminobutyric acid and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
B cell-derived GABA elicits IL-10
Topics: Animals; B-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Female; gamma-Aminobutyric A | 2021 |
B cells secrete GABA, which provokes a pro-tumor immune microenvironment.
Topics: gamma-Aminobutyric Acid; Humans; Macrophages; Neoplasms; T-Lymphocytes; Tumor Microenvironment | 2022 |
Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression.
Topics: A549 Cells; Animals; beta Catenin; CD8-Positive T-Lymphocytes; Cell Proliferation; Drug Resistance, | 2022 |
Targeting GABA signalling for cancer treatment.
Topics: Cell Communication; gamma-Aminobutyric Acid; Humans; Neoplasms; Signal Transduction | 2022 |
Internal dosimetry studies of
Topics: Animals; gamma-Aminobutyric Acid; Heterocyclic Compounds, 1-Ring; Humans; Male; Monte Carlo Method; | 2022 |
Localization of chemical synapses and modulatory release sites in the cardiac ganglion of the crab, Cancer borealis.
Topics: Animals; Brachyura; gamma-Aminobutyric Acid; Ganglia, Invertebrate; Neoplasms; Neurotransmitter Agen | 2022 |
Red Ginseng Extract and γ-Aminobutyric Acid Synergistically Enhance Immunity Against Cancer Cells and Antitumor Metastasis Activity in Mice.
Topics: Animals; Cytokines; gamma-Aminobutyric Acid; Interferon-gamma; Killer Cells, Natural; Mice; Neoplasm | 2023 |
Bridging the Metabolic Parallels Between Neurological Diseases and Cancer.
Topics: Dipeptides; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Neoplasms; Organophosphorus Compounds | 2021 |
[Palliative care in geriatrics].
Topics: Alzheimer Disease; Analgesics; Cooperative Behavior; gamma-Aminobutyric Acid; Geriatrics; Germany; H | 2013 |
β-Blockers and metastasis in non-small-cell lung cancer.
Topics: Adrenergic beta-Antagonists; Animals; Carcinoma, Non-Small-Cell Lung; gamma-Aminobutyric Acid; Human | 2013 |
[Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy].
Topics: Antineoplastic Agents; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neoplasms; Organoplatinum | 2013 |
Glutaminase catalyzes reaction of glutamate to GABA.
Topics: Brain; gamma-Aminobutyric Acid; Glucose; Glutamate Decarboxylase; Glutamic Acid; Glutaminase; Glycol | 2014 |
Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?
Topics: Aged; Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy, Adjuvant; C | 2015 |
Agonizing integrin antagonists?
Topics: Animals; Benzocycloheptenes; Cell Proliferation; Dose-Response Relationship, Drug; gamma-Aminobutyri | 2009 |
Rat medium-term multi-organ carcinogenesis bioassay of Agaricus blazei Murrill fruit-body extract.
Topics: Agaricus; Animals; Body Weight; Carcinogens; Drinking; Eating; Female; Fruiting Bodies, Fungal; gamm | 2010 |
Gabapentin in the treatment of hiccups in patients with advanced cancer: a 5-year experience.
Topics: Adult; Aged; Aged, 80 and over; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Dose- | 2010 |
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin.
Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Cyclohexanecarboxylic Aci | 2010 |
[Pitfalls in the treatment of neuropathic pain in patients with cancer].
Topics: Aged; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2011 |
Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors.
Topics: Animals; Bombesin; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; Drug Ev | 2011 |
Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.
Topics: Aged; Analgesia; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Motor Activ | 2011 |
Risk of cancer in patients exposed to gabapentin in two electronic medical record systems.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; California; Case-Control Studies; Cohort Studies; | 2012 |
[Retrospective evaluation of pregabalin for cancer-related neuropathic pain].
Topics: Aged; Analgesics; Disorders of Excessive Somnolence; Female; gamma-Aminobutyric Acid; Humans; Male; | 2012 |
Oncosecretomics coupled to bioenergetics identifies α-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes.
Topics: 2-Aminoadipic Acid; Animals; Biomarkers, Tumor; Cells, Cultured; Energy Metabolism; gamma-Aminobutyr | 2012 |
[Action of gamma-aminobutyric acid in the control of cancer].
Topics: Amino Acids; Antifibrinolytic Agents; gamma-Aminobutyric Acid; Neoplasms; Properdin | 1962 |
The pattern of gabapentin use in a tertiary palliative care unit.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; G | 2003 |
Effects of germinated brown rice extracts with enhanced levels of GABA on cancer cell proliferation and apoptosis.
Topics: Animals; Apoptosis; Cell Division; Female; gamma-Aminobutyric Acid; Germination; HeLa Cells; Humans; | 2004 |
[Gabapentin (Neurontin) and cancer pain: a pilot study].
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2004 |
Re: Pruritus in patients with advanced cancer.
Topics: Cholestasis; Cholestyramine Resin; GABA Agonists; gamma-Aminobutyric Acid; Humans; Narcotic Antagoni | 2005 |
Gabapentin in the treatment of severe sweating experienced by advanced cancer patients.
Topics: Adult; Aged; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Ami | 2006 |
Experience with gabapentin for neuropathic pain in adolescents: report of five cases.
Topics: Adolescent; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob | 2006 |
Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain.
Topics: Aged; Amines; Amitriptyline; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents, Tricyclic; | 2006 |
Survey of management of acquired nystagmus in the United Kingdom.
Topics: Amines; Baclofen; Cyclohexanecarboxylic Acids; Drug Utilization; Excitatory Amino Acid Antagonists; | 2007 |
Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.
Topics: Anoikis; Apoptosis; Benzocycloheptenes; Cell Culture Techniques; Cell Death; Endothelium, Vascular; | 2006 |
Role of biogenic amines and their related enzymes in cancer cases.
Topics: Amine Oxidase (Copper-Containing); Biogenic Amines; Female; gamma-Aminobutyric Acid; Glutamates; Hum | 1981 |
Gabapentin for lancinating neuropathic pain.
Topics: Acetates; Acquired Immunodeficiency Syndrome; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabap | 1998 |
Gabapentin, an adjuvant treatment for neuropathic pain in a cancer hospital.
Topics: Acetates; Amines; Analgesics; Cancer Care Facilities; Cyclohexanecarboxylic Acids; Gabapentin; gamma | 2000 |
Differences in gabapentin efficacy for cancer pain more apparent than real?
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Huma | 2001 |
Gabapentin for opiod-related myoclonus in cancer patients.
Topics: Acetates; Amines; Analgesics, Opioid; Anticonvulsants; Cyclohexanecarboxylic Acids; Gabapentin; gamm | 2001 |
Dimethyl sulfoxide therapy as toxicity-reducing agent and potentiator of cyclophosphamide in the treatment of different types of cancer.
Topics: Adolescent; Adult; Aged; Cyclophosphamide; Dimethyl Sulfoxide; Drug Synergism; Female; gamma-Aminobu | 1975 |